Amyris and DSM close US$50M strategic transaction on farnesene supply

The deal licenses DSM rights to assume the supply of farnesene to Givaudan

Related Articles

FormattedPicture

PACKAGING & TECHNOLOGY NEWS

Protecting medical and pharmaceutical solutions while driving up the environmental sustainability of packaging was a major theme at this year’s CPHI trade show in... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

The World Food Programme (WFP) is reporting a rapid accelerated red alert on global hunger and malnutrition levels. Compared to 2019, acute food insecurity has... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Swiss-based Biotech company, Evolva, released its half-year report for 2022, presenting a total revenue from customer contracts of CHF8.1 million (US$8.4 million). The... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Spain-based Nektium is launching an organic version of its elderberry extract amid increasing consumer demand for natural ingredients. Though there have been elderberry... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Glanbia delivered 13% growth in the first half of 2022, driven by price increases and volume growth. Group revenues reached €2.8 billion (US$2.9 billion), while... Read More

trans